New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
10:00 EDTABBV, URBN, TRGP, PTEN, PKE, ORCL, LMCA, HP, ETP, LLY, DRWI, CP, BAC, BHI, BRGYY, ALU, WBMDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AbbVie (ABBV) upgraded to Overweight from Equal Weight at Barclays... Alcatel-Lucent (ALU) upgraded to Overweight from Neutral at JPMorgan... BG Group (BRGYY) upgraded to Buy from Hold at Canaccord... Baker Hughes (BHI) upgraded to Neutral from Sell at Guggenheim... Bank of America (BAC) upgraded to Buy from Hold at Deutsche Bank... Canadian Pacific (CP) upgraded to Outperformer from Sector Performer at CIBC... DragonWave (DRWI) upgraded to Buy from Neutral at H.C. Wainwright... Eli Lilly (LLY) upgraded to Equal Weight from Underweight at Barclays... Energy Transfer Partners (ETP) upgraded to Outperform at Wells Fargo... Helmerich & Payne (HP) upgraded to Neutral from Sell at Guggenheim... Liberty Media (LMCA) upgraded at Morgan Stanley... Men's Wearhouse (MW) upgraded at Stifel... Oracle (ORCL) upgraded to Overweight from Neutral at Atlantic Equities... Park Electrochemical (PKE) upgraded to Buy from Hold at Needham... Patterson-UTI Energy (PTEN) upgraded to Neutral from Sell at Guggenheim... Targa Resources (TRGP) upgraded to Conviction Buy from Buy at Goldman... Urban Outfitters (URBN) upgraded to Outperform from Neutral at Macquarie... WebMD (WBMD) upgraded at Stifel.
News For ABBV;ALU;BRGYY;BHI;BAC;CP;DRWI;LLY;ETP;HP;LMCA;ORCL;PKE;PTEN;TRGP;URBN;WBMD From The Last 14 Days
Check below for free stories on ABBV;ALU;BRGYY;BHI;BAC;CP;DRWI;LLY;ETP;HP;LMCA;ORCL;PKE;PTEN;TRGP;URBN;WBMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
September 4, 2014
06:40 EDTBACAgencies finalize liquidity rule for large banks
The Federal Reserve Board, the Federal Deposit Insurance Corporation, and the Office of the Comptroller of the Currency finalized a rule yesterday that they said would strengthen the liquidity positions of large financial institutions. The rule will for the first time create a standardized minimum liquidity requirement for large and internationally active banking organizations., according to the agencies. Each institution will be required to hold high quality, liquid assets, or HQLA, such as central bank reserves and government and corporate debt that can be converted easily and quickly into cash in an amount equal to or greater than its projected cash outflows minus its projected cash inflows during a 30-day stress period, the agencies explained. The ratio of the firm’s liquid assets to its projected net cash outflow is its “liquidity coverage ratio,” or LCR, they said. The LCR will apply to all banking organizations with $250B or more in total consolidated assets or $10B or more in on-balance sheet foreign exposure and to these banking organizations’ subsidiary depository institutions that have assets of $10B or more, the agencies reported. The rule also will apply a less stringent, modified LCR to bank holding companies and savings and loan holding companies that do not meet these thresholds, but have $50B or more in total assets. Bank holding companies and savings and loan holding companies with substantial insurance or commercial operations are not covered by the final rule. The final rule is largely identical to the proposed rule, with a few key adjustments in response to comments from the public, the agencies stated. Those adjustments include changes to the range of corporate debt and equity securities included in HQLA, a phasing-in of daily calculation requirements, a revised approach to address maturity mismatch during a 30-day period, and changes in the stress period, calculation frequency, and implementation timeline for the bank holding companies and savings and loan companies subject to the modified LCR. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
06:05 EDTPTENPatterson-UTI Energy reports 208 rigs in operation in August
Subscribe for More Information
September 3, 2014
16:20 EDTABBVOn The Fly: Closing Wrap
Stocks on Wall Street began the session in positive territory after Russian President Vladimir Putin said he had an outline for a cease-fire plan for eastern Ukraine and was closing in an agreement. The averages hit their highs shortly after the open and the Nasdaq was the first index to cross into negative territory as it was weighed down by Apple's (AAPL) decline. The market moved in a narrow range as investors anticipated the Fed’s Beige Book report, scheduled for release mid-afternoon. The report was fairly benign and the market limped into the close, with volume remaining light. ECONOMIC EVENTS: U.S. factory orders rose 10.5% in July, which was a bit below the forecast for 11.0% growth. The Fed's Beige Book stated that the pace of growth did not change significantly in any of the central bank's 12 regions during a six week period ended in August compared with the previous six week period. COMPANY NEWS: Shares of Apple retreated $4.36, or 4.22%, to $98.94 after research firm Pacific Crest advised investors to take some profits in the stock. Analyst Andy Hargreaves forecast the percentage of new iPhone users who buy the next version of the device beyond the iPhone 6 is likely to decline versus prior cycles. The stock likely has only limited room to increase, according to Hargreaves, who said he would probably downgrade Apple unless new products that can generate billions of dollars in new operating profit are launched at its September 9 event. MAJOR MOVERS: Among the notable gainers was Infinity Pharmaceuticals (INFI), which surged $4.81, or 44.05%, to $15.73 after the company announced a cancer drug collaboration with AbbVie (ABBV) and a master clinical supply agreement with Roche (RHHBY). Also higher was Mobileye (MBLY), which jumped $3.94, or 9.16%, to $46.97 ahead of its second quarter earnings report, which is due tomorrow morning. Among the noteworthy losers was Repros Therapeutics (RPRX), which fell $4.11, or 18.55%, to $18.05 after FDA briefing documents ahead of a panel on T-normalizing therapies prompted Piper Jaffray to downgrade the stock to Neutral from Overweight. Also lower after its earnings report was apparel company Vince Holding (VNCE), which fell $4.47, or 11.54%, to $34.27. Analysts at Piper Jaffray attributed the post-earnings weakness to investor concerns over heightened inventory levels, but the firm said it still sees Vince as one of the best small cap growth names in its space and would be "aggressive buyers" on the weakness. INDEXES: The Dow edged up 10.72, or 0.06%, to 17,078.28, the Nasdaq fell 25.62, or 0.56%, to 4,572.56, and the S&P 500 slipped 1.56, or 0.08%, to 2,000.72.
16:09 EDTABBVAbbVie backs Q3 adjusted EPS view 77c-79c, consensus 77c
16:09 EDTABBVAbbVie confirms FY14 adjusted EPS view $3.06-$3.16, consensus $3.16
Subscribe for More Information
13:03 EDTORCLConcur advances after report says acquisition being explored
Subscribe for More Information
13:02 EDTABBVAbbVie, Calico announce collaboration
Subscribe for More Information
12:58 EDTHPHelmerich & Payne Chief Administrative Officer Steven Mackey to retire
Subscribe for More Information
12:33 EDTABBVOn The Fly: Midday Wrap
Stocks on Wall Street were higher to begin the day, as reports spurred optimism that a ceasefire agreement between Russia and the Ukraine may soon be reached. The move was short lived, as the averages turned mixed during the second hour of trading. Shares of Apple (AAPL) are weighing down the Nasdaq after an analyst recommended investors take some profits in the stock. ECONOMIC EVENTS: In the U.S., factory orders rose 10.5% in July, which was a bit below the forecast for 11.0% growth. The Fed's Beige Book is scheduled to be released at 2:00 pm ET. In Europe, the final reading of Eurozone services PMI was knocked down to 53.1 from a preliminary 53.5 reading, mirroring the lowering of the Eurozone manufacturing PMI reading yesterday. COMPANY NEWS: Shares of Apple retreated 4% after research firm Pacific Crest advised investors to take some profits in the stock. Pacific Crest analyst Andy Hargreaves forecast the percentage of new iPhone users who buy the next version of the device beyond the iPhone 6 is likely to decline versus prior cycles. The stock likely has only limited room to increase, according to Hargreaves, who said he would probably downgrade Apple unless new products that can generate billions of dollars in new operating profit are launched at its September 9 event... Carmakers reported on August vehicle sales in the U.S., with Chrysler (FIATY) reporting a 20% increase, Ford stating that sales rose slightly compared to the prior year and General Motors (GM) posting a 1.2% decline in sales. MAJOR MOVERS: Among the notable gainers was Infinity Pharmaceuticals (INFI), which jumped 46% after the company announced a cancer drug collaboration with AbbVie (ABBV) and a master clinical supply agreement with Roche (RHHBY). Also higher was Mobileye (MBLY), which gained nearly 10% after Morgan Stanley wrote that the stock could rise "towards $100" if the company maintains its current market, gross margins and earnings position. Mobileye is scheduled to report on its second quarter results tomorrow morning, which will be its first quarterly report since its August IPO. Among the noteworthy losers was Repros Therapeutics (RPRX), which dropped 15% after newly posted FDA briefing documents regarding a panel on T-normalizing therapies prompted Piper Jaffray to downgrade the stock to Neutral from Overweight. Also lower following its earnings report was apparel company Vince Holding (VNCE), which fell 11%. INDEXES: Near midday, the Dow was up 33.71, or 0.2%, to 17,101.27, the Nasdaq was down 23.24, or 0.51%, to 4,574.95, and the S&P 500 was down 0.64, or 0.03%, to 2,001.64.
10:00 EDTBACOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:15 EDTORCL, ABBVOn The Fly: Pre-market Movers
Subscribe for More Information
09:02 EDTBACFirst South Bancorp purchases banking operations in North Carolina
First South Bancorp (FSBK) announced the signing of an agreement under which the Bank has agreed to purchase the branch banking operations of nine locations in North Carolina from Bank of America (BAC). The branch offices are located in Elizabethtown, Goldsboro, Kenansville, Kinston, Kitty Hawk, Morehead City, Mount Olive, Wallace and Wilson, North Carolina. The purchase is expected to add approximately $261.4M of deposits. The Bank has also agreed to purchase the fixed assets and a small amount of loans related to the purchased branches. The Bank expects the transaction to close in the fourth quarter of 2014, subject to approval by regulators and satisfaction of customary closing conditions. After the purchase of the branches, the Bank's franchise will increase from 26 to 35 banking offices. The transaction is expected to increase assets from $711M at June 30, 2014 to approximately $972M and deposits from $593M to approximately $854M at close.
07:59 EDTABBVInfinity Pharmaceuticals to host conference call
Conference call to discuss the strategic collaboration with AbbVie Inc to develop and commercialize duvelisib will be held on September 3 at 8:30 am. Webcast Link
07:48 EDTORCLConcur a highly desirable M&A target, says UBS
Subscribe for More Information
07:29 EDTBACFinal liquidity, swaps margin rules to be unveiled today, Reuters says
Subscribe for More Information
07:19 EDTBACBank of America downgraded to Neutral from Buy at Nomura
Price target lowered to $17 from $18.
06:48 EDTABBVInfinity, AbbVie announce global strategic collaboration to develop duvelisib
Infinity Pharmaceuticals (INFI) and AbbVie (ABBV) announced that they have entered into a global collaboration to develop and commercialize duvelisib, Infinity’s oral inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMOTM, a Phase 2 study in patients with iNHL, and DUOTM, a Phase 3 study in patients with CLL. Under the terms of the agreement, Infinity will receive an upfront payment of $275M and is eligible to receive up to $530M in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405M for the achievement of milestones through the first commercial sale of duvelisib. In the U.S., the companies will jointly commercialize duvelisib and will share equally in any potential profits. Outside the U.S., AbbVie will be responsible for the conduct and funding of commercialization of duvelisib, and Infinity is eligible to receive tiered double-digit royalties on net product sales. Development and commercialization activities under the collaboration will be managed through a shared governance structure. In the U.S., Infinity and AbbVie will jointly commercialize duvelisib, assuming regulatory approval, with Infinity booking sales, and will share equally in any potential profits or losses. Outside the U.S., AbbVie will be responsible for conducting and funding of any commercialization of duvelisib, and Infinity is eligible to receive tiered royalties on net product sales, with percentages ranging from 23.5%-30.5%. For sales of duvelisib in the U.S., AbbVie and Infinity will share equally the existing royalty obligations to Mundipharma International Corporation Limited/Purdue Pharmaceutical Products L.P., and Infinity will be responsible for these royalty obligations outside of the U.S. Infinity will also be responsible for the existing royalty obligations to Millennium: The Takeda Oncology Company for sales of duvelisib worldwide. As part of the strategic collaboration, the companies will share responsibility for the conduct of specific trials specified within an agreed-upon global development plan, with each company leading the development of certain trials within the plan. For the initial global development plan agreed to by the companies, Infinity will fund the trials it conducts and the companies will share equally the funding of trials conducted by AbbVie. The agreement includes plans to launch multiple Phase 2 and Phase 3 studies of duvelisib in hematologic malignancies over the next several years.
06:48 EDTABBVInfinity Pharmaceuticals, AbbVie announce global strategic collaboration
Subscribe for More Information
06:35 EDTBACJPMorgan in talks to sell oil-supply agreement to Bank of America, WSJ says
Subscribe for More Information
06:34 EDTBACFBI hasn't found evidence JPMorgan hack hit other big banks, WSJ reports
The FBI hasn't found any evidence to suggest that the recent breach at JPMorgan hit any of the other big U.S. banks, the Wall Street Journal reports, citing four people close to the probe. JPMorgan said it isn't experiencing "unusual amounts of fraud," and, according to two sources, consumers "likely don't face a serious risk." Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use